Verrica Pharmaceuticals schedules conference call to discuss Q2 results, corporate update
VRCA•Conference call and webcast scheduled for Aug. 6
- Verrica schedules a conference call, webcast on Aug. 6, 2026 to report Q2 results ended June 30, 2026, issue a corporate update.
- Webcast replay set to remain available for 90 days on https://www.verrica.com.
Related News
Johnson & Johnson's Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) receives U.S. FDA priority review as potential first-in-class Egfr- and Met-targeted subcutaneous treatment for advanced head and neck cancer
JNJ•
U.S. June personal income data
SPY•
